Literature DB >> 15275189

Leishmania and the pathogenesis of HIV infection.

M Tremblay1, M Olivier, R Bernier.   

Abstract

Acquired immunodeficiency syndrome (AIDS) and leishmaniasis overlap in several parts of the world, and microorganisms responsible for these human diseases infect and replicate within the macrophage. Therefore, the opportunity that the pathogenesis of the human immunodeficiency virus (HIV) and Leishmania infections could be modulated within dually infected individual is optimized. The most prominent clinical feature of AIDS is the development of debilitating secondary infections induced by several opportunistic microorganisms, including protozoa. Michel Tremblay, Martin Olivier and Richard Bernier here focus on the recently reported information on the putative cofactor role that the intracellular pathogen of the genus Leishmania may play in the pathogenesis of HIV infection.

Entities:  

Year:  1996        PMID: 15275189     DOI: 10.1016/0169-4758(96)10021-1

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  10 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Phagocytic activity in human immunodeficiency virus type 1 infection.

Authors:  Agostino Pugliese; Valerio Vidotto; Tiziana Beltramo; Donato Torre
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

3.  Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases.

Authors:  C Agostoni; N Dorigoni; A Malfitano; L Caggese; G Marchetti; S Corona; S Gatti; M Scaglia
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 4.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  A study of haematological and bone marrow changes in symptomatic patients with human immune deficiency virus infection with special mention of functional iron deficiency, anaemia of critically ill and haemophagocytic lymphohistiocytosis.

Authors:  Jyoti Kotwal; Vikram Singh; Anupam Kotwal; Vibha Dutta; Velu Nair
Journal:  Med J Armed Forces India       Date:  2013-02-23

Review 6.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 7.  Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.

Authors:  Gláucia F Cota; Marcos R de Sousa; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2011-06-07

8.  Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Leishmania Transmission at the Village Level in Bihar, India.

Authors:  Kristien Cloots; Pia Marino; Sakib Burza; Naresh Gill; Marleen Boelaert; Epco Hasker
Journal:  Front Cell Infect Microbiol       Date:  2021-03-11       Impact factor: 5.293

9.  Morphine-induced neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines and nitric oxide.

Authors:  Prati Pal Singh; Priya Singal
Journal:  J Neuroimmune Pharmacol       Date:  2007-10-10       Impact factor: 7.285

10.  Strychnos pseudoquina and Its Purified Compounds Present an Effective In Vitro Antileishmanial Activity.

Authors:  Paula Sousa Lage; Pedro Henrique Rocha de Andrade; Amanda de Santana Lopes; Miguel Angel Chávez Fumagalli; Diogo Garcia Valadares; Mariana Costa Duarte; Daniela Pagliara Lage; Lourena Emanuele Costa; Vivian Tamietti Martins; Tatiana Gomes Ribeiro; José Dias de Souza Filho; Carlos Alberto Pereira Tavares; Rodrigo Maia de Pádua; João Paulo Viana Leite; Eduardo Antonio Ferraz Coelho
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-30       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.